Advances in non-covalent based inhibitors targeting Myc: a promising approach for cancer treatment

Future Medicinal ChemistryAhead of Print EditorialAdvances in non-covalent based inhibitors targeting Myc: a promising approach for cancer treatmentVipendra Kumar Singh, Naina Rajak, Rajanish Giri & Neha GargVipendra Kumar Singh https://orcid.org/0000-0003-4744-2474School of Biosciences & Bioengineering, Indian Institute of Technology Mandi, VPO Kamand, Mandi-175075, HP, IndiaSearch for more papers by this author, Naina Rajak https://orcid.org/0009-0009-0653-3071Faculty of Ayurveda, Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, IndiaSearch for more papers by this author, Rajanish Giri https://orcid.org/0000-0002-2046-836XSchool of Biosciences & Bioengineering, Indian Institute of Technology Mandi, VPO Kamand, Mandi-175075, HP, IndiaSearch for more papers by this author & Neha Garg *Author for correspondence: Tel.: +91 981 808 2907; E-mail Address: nehagarg@bhu.ac.inhttps://orcid.org/0000-0003-2227-8292Faculty of Ayurveda, Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, IndiaSearch for more papers by this authorPublished Online:12 Dec 2023https://doi.org/10.4155/fmc-2023-0332AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: cancersMyc proteinnon-covalent inhibitorsoncogeneundruggableReferences1. Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J. Hematol. Oncol. 14(1), 121 (2021).Crossref, Medline, CAS, Google Scholar2. Llombart V, Mansour MR. Therapeutic targeting of “undruggable” MYC. eBioMedicine 75, 103756 (2022).Crossref, Medline, CAS, Google Scholar3. DePinho R, Mitsock L, Hatton K et al. Myc family of cellular oncogenes. J. Cell. Biochem. 33(4), 257–266 (1987).Crossref, Medline, CAS, Google Scholar4. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Target. Ther. 3(1), 5 (2018).Crossref, Medline, Google Scholar5. Bretones G, Delgado MD, León J. Myc and cell cycle control. Biochim. Biophys. Acta 1849(5), 506–516 (2015).Crossref, Medline, CAS, Google Scholar6. Duffy MJ, O'Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat. Rev. 94, 102154 (2021).Crossref, Medline, CAS, Google Scholar7. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290(5806), 475–480 (1981).Crossref, Medline, CAS, Google Scholar8. Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol. Cancer 20(1), 3 (2021).Crossref, Medline, Google Scholar9. Karadkhelkar NM, Lin M, Eubanks LM, Janda KD. Demystifying the Druggability of the MYC Family of Oncogenes. J. Am. Chem. Soc. 145(6), 3259–3269 (2023).Crossref, Medline, CAS, Google Scholar10. Saeed H, Leibowitz BJ, Zhang L, Yu J. Targeting Myc-driven stress addiction in colorectal cancer. Drug Resist. Updat. 69, 100963 (2023).Crossref, Medline, CAS, Google Scholar11. Adhav VA, Saikrishnan K. The Realm of Unconventional Noncovalent Interactions in Proteins: Their Significance in Structure and Function. ACS Omega 8(25), 22268–22284 (2023).Crossref, Medline, CAS, Google Scholar12. Aljoundi A, Bjij I, El Rashedy A, Soliman MES. Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective. Protein J. 39(2), 97–105 (2020).Crossref, Medline, CAS, Google Scholar13. Ross J, Miron CE, Plescia J et al. Targeting MYC: from understanding its biology to drug discovery. Eur. J. Med. Chem. 213, 113137 (2021).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 0 times History Received 10 November 2023 Accepted 27 November 2023 Published online 12 December 2023 Information© 2023 Newlands PressKeywordscancersMyc proteinnon-covalent inhibitorsoncogeneundruggableAuthor contributionsAll authors wrote the manuscript. All authors have given approval to the final version of the manuscript.Financial disclosureThe authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download